LUCY vs. CTSO, INO, APYX, ICAD, LUCD, DHAI, CLGN, BLAC, NTRB, and NXL
Should you be buying Innovative Eyewear stock or one of its competitors? The main competitors of Innovative Eyewear include Cytosorbents (CTSO), Inovio Pharmaceuticals (INO), Apyx Medical (APYX), iCAD (ICAD), Lucid Diagnostics (LUCD), DIH Holding US (DHAI), CollPlant Biotechnologies (CLGN), Bellevue Life Sciences Acquisition (BLAC), Nutriband (NTRB), and Nexalin Technology (NXL). These companies are all part of the "medical equipment" industry.
Innovative Eyewear vs.
Innovative Eyewear (NASDAQ:LUCY) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, community ranking, risk, valuation and dividends.
Cytosorbents has a net margin of -49.47% compared to Innovative Eyewear's net margin of -514.01%. Innovative Eyewear's return on equity of -115.86% beat Cytosorbents' return on equity.
Innovative Eyewear has a beta of 2.67, suggesting that its stock price is 167% more volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500.
Innovative Eyewear presently has a consensus target price of $20.00, suggesting a potential upside of 278.07%. Cytosorbents has a consensus target price of $4.67, suggesting a potential upside of 371.38%. Given Cytosorbents' higher probable upside, analysts plainly believe Cytosorbents is more favorable than Innovative Eyewear.
Cytosorbents received 437 more outperform votes than Innovative Eyewear when rated by MarketBeat users. However, 100.00% of users gave Innovative Eyewear an outperform vote while only 74.79% of users gave Cytosorbents an outperform vote.
1.0% of Innovative Eyewear shares are held by institutional investors. Comparatively, 32.9% of Cytosorbents shares are held by institutional investors. 6.4% of Innovative Eyewear shares are held by company insiders. Comparatively, 6.6% of Cytosorbents shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Innovative Eyewear has higher earnings, but lower revenue than Cytosorbents. Cytosorbents is trading at a lower price-to-earnings ratio than Innovative Eyewear, indicating that it is currently the more affordable of the two stocks.
In the previous week, Cytosorbents had 2 more articles in the media than Innovative Eyewear. MarketBeat recorded 4 mentions for Cytosorbents and 2 mentions for Innovative Eyewear. Innovative Eyewear's average media sentiment score of 1.90 beat Cytosorbents' score of 0.37 indicating that Innovative Eyewear is being referred to more favorably in the media.
Summary
Cytosorbents beats Innovative Eyewear on 11 of the 18 factors compared between the two stocks.
Get Innovative Eyewear News Delivered to You Automatically
Sign up to receive the latest news and ratings for LUCY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Innovative Eyewear Competitors List
Related Companies and Tools
This page (NASDAQ:LUCY) was last updated on 1/31/2025 by MarketBeat.com Staff
